Iovance Biotherapeutics — Third Quarter 2026 Earnings Summary

Iovance Biotherapeutics reported record third-quarter 2026 total revenue of approximately $122 million, representing an 80% year-over-year increase driven by strong demand for its Amtagvi therapy. The company achieved a gross margin of roughly 60% and announced that more than 1,000 patients have been commercially treated with Amtagvi to date. Clinical updates included a 24.6% objective response rate in non-squamous metastatic non-small-cell lung cancer patients and a 55.6% response rate in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Iovance remains on track to meet its full-year 2026 revenue guidance of $410 to $420 million while expanding its authorized treatment center network globally.